Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review

  • ID: 4284981
  • SWOT Analysis
  • 53 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Alkermes Plc
  • Celgene Corp
  • Cell Medica Ltd
  • Genentech Inc
  • MORE
Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its lead candidate tabelecleucel, formerly ATA129, in Phase 3 for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab

Atara Biotherapeutics Inc Key Recent Developments

May 08, 2018 Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress
May 07, 2018 Atara Biotherapeutics Appoints Dietmar Berger As Global Head Of Research And Development
Apr 09, 2018 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 22, 2018 Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alkermes Plc
  • Celgene Corp
  • Cell Medica Ltd
  • Genentech Inc
  • MORE
Section 1 - About the Company
  • Atara Biotherapeutics Inc - Key Facts
  • Atara Biotherapeutics Inc - Key Employees
  • Atara Biotherapeutics Inc - Key Employee Biographies
  • Atara Biotherapeutics Inc - Major Products and Services
  • Atara Biotherapeutics Inc - History
  • Atara Biotherapeutics Inc - Company Statement
  • Atara Biotherapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Atara Biotherapeutics Inc - Business Description
  • R&D Overview
  • Atara Biotherapeutics Inc - Corporate Strategy
  • Atara Biotherapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Atara Biotherapeutics Inc - Strengths
  • Atara Biotherapeutics Inc - Weaknesses
  • Atara Biotherapeutics Inc - Opportunities
  • Atara Biotherapeutics Inc - Threats
  • Atara Biotherapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Atara Biotherapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 08, 2018: Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress
  • Apr 09, 2018: Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • Mar 22, 2018: Atara Biotherapeutics to Participate in Three Upcoming Immuno-Oncology Conferences
  • Feb 27, 2018: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress
  • Feb 21, 2018: Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018
  • Jan 08, 2018: ArTara Therapeutics Announces Addition of Randall Marshall, MD as Chief Medical Officer
  • Nov 09, 2017: Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights
  • Aug 07, 2017: Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights
  • May 10, 2017: Atara Biotherapeutics appoints new SVP and global commercial head
  • May 04, 2017: Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Atara Biotherapeutics Inc, Key Facts
  • Atara Biotherapeutics Inc, Key Employees
  • Atara Biotherapeutics Inc, Key Employee Biographies
  • Atara Biotherapeutics Inc, Major Products and Services
  • Atara Biotherapeutics Inc, History
  • Atara Biotherapeutics Inc, Other Locations
  • Atara Biotherapeutics Inc, Subsidiaries
  • Atara Biotherapeutics Inc, Key Competitors
  • Atara Biotherapeutics Inc, Ratios based on current share price
  • Atara Biotherapeutics Inc, Annual Ratios
  • Atara Biotherapeutics Inc, Annual Ratios (Cont...1)
  • Atara Biotherapeutics Inc, Interim Ratios
  • Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Atara Biotherapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Atara Biotherapeutics Inc, Performance Chart (2013 - 2017)
  • Atara Biotherapeutics Inc, Ratio Charts
  • Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alkermes Plc
  • Celgene Corp
  • Cell Medica Ltd
  • Genentech Inc
  • Janssen Research & Development LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll